glp 1 agonist liraglutide FDA Approves First Generic Once-Daily Injection GLP-1 Receptor Agonists as Treatments

"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis"

Approach: His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health

doi: 10.1016/S0140-6736(11)60814-3, PMID: [DOI] [PubMed] [Google Scholar] 2

One of the major reasons is the high dropout rate, 11 possibly due to the nausea-related side effects and importantly the fact that these formulations are till date injectable